Refanezumab

Source: Wikipedia, the free encyclopedia.
Refanezumab
Humanized (from mouse)
Targetmyelin-associated glycoprotein
Clinical data
Other namesGSK249320
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6608H10156N1732O2064S44
Molar mass148298.64 g·mol−1

Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke.[1][2]

This drug was developed by

GlaxoSmithKline
.

References

  1. ^ "Refanezumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association..
  2. PMID 28228578
    .
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Refanezumab&oldid=1177181628"